Company Description
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders.
It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.
It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome.
Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation.
The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
| Country | United States |
| IPO Date | Jul 31, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 165 |
| CEO | Dr. Scott N. Braunstein M.D. |
Contact Details
Address: 5 Radnor Corporate Center Radnor, Pennsylvania United States | |
| Website | https://marinuspharma.com |
Stock Details
| Ticker Symbol | MRNS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001267813 |
| CUSIP Number | 56854Q200 |
| ISIN Number | US56854Q2003 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Scott N. Braunstein M.D. | Chief Executive Officer, President & Chairman |
| Steven E. Pfanstiel C.M.A., M.B.A. | Chief Operating Officer, Chief Financial Officer & Treasurer |
| Christina Shafer | Chief Commercial Officer |
| David Czekai | Chief Chemistry, Manufacturing & Controls Officer |
| Dr. Alex Aimetti Ph.D. | Chief Scientific Officer |
| Dr. Joseph Hulihan M.D. | Chief Medical Officer |
| Dr. Kimberly A. McCormick Pharm.D. | Chief Regulatory & Quality Assurance Officer |
| Martha E. Manning Esq., J. D. | Senior Vice President, General Counsel & Secretary |
| Molly Cameron | Director of Corporate Communications & Investor Relations |
| Sonya Weigle | Senior Vice President of Investor Relations, Human Resources & Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | SC 14D9 | Filing |
| Jan 08, 2025 | SC TO-T | Filing |
| Jan 07, 2025 | SCHEDULE 13G | Filing |
| Jan 02, 2025 | SC TO-C | Filing |
| Dec 30, 2024 | SC14D9C | Filing |
| Dec 30, 2024 | 8-K | Current Report |
| Dec 30, 2024 | 8-K | Current Report |
| Dec 23, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |